ES2587344T3 - Ratón transgénico que comprende un polinucleótido que codifica C5aR humano o humanizado - Google Patents

Ratón transgénico que comprende un polinucleótido que codifica C5aR humano o humanizado Download PDF

Info

Publication number: ES2587344T3
Authority: ES; Spain
Prior art keywords: c5ar; human; gene; mouse; mice
Prior art date: 2003-12-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES10196615.8T

Other languages

English (en)

Spanish (es)

Inventor

Charles Reay Mackay

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-24

Filing date

2004-12-24

Publication date

2016-10-24

2003-12-24 Priority claimed from AU2003907150A external-priority patent/AU2003907150A0/en

2004-12-24 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

2016-10-24 Application granted granted Critical

2016-10-24 Publication of ES2587344T3 publication Critical patent/ES2587344T3/es

2024-12-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 title abstract description 59
102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title abstract description 52
102000040430 polynucleotide Human genes 0.000 title abstract description 10
108091033319 polynucleotide Proteins 0.000 title abstract description 10
239000002157 polynucleotide Substances 0.000 title abstract description 10
238000011830 transgenic mouse model Methods 0.000 title abstract description 10
101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 abstract description 54
101000867985 Mus musculus C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 abstract description 13
108090000623 proteins and genes Proteins 0.000 description 55
108090000765 processed proteins & peptides Proteins 0.000 description 48
241000699670 Mus sp. Species 0.000 description 44
238000000034 method Methods 0.000 description 42
150000001413 amino acids Chemical group 0.000 description 40
235000001014 amino acid Nutrition 0.000 description 39
150000001875 compounds Chemical class 0.000 description 37
241001465754 Metazoa Species 0.000 description 36
210000004027 cell Anatomy 0.000 description 34
108020004414 DNA Proteins 0.000 description 32
102000053602 DNA Human genes 0.000 description 30
230000014509 gene expression Effects 0.000 description 30
230000009261 transgenic effect Effects 0.000 description 27
102000004196 processed proteins & peptides Human genes 0.000 description 23
241000699666 Mus <mouse, genus> Species 0.000 description 22
230000027455 binding Effects 0.000 description 22
210000001671 embryonic stem cell Anatomy 0.000 description 20
239000012634 fragment Substances 0.000 description 20
150000007523 nucleic acids Chemical class 0.000 description 20
235000018102 proteins Nutrition 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 20
239000000126 substance Substances 0.000 description 17
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
102000039446 nucleic acids Human genes 0.000 description 15
108020004707 nucleic acids Proteins 0.000 description 15
-1 Asn Amino Acid Chemical class 0.000 description 14
210000000440 neutrophil Anatomy 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
108700019146 Transgenes Proteins 0.000 description 12
239000003446 ligand Substances 0.000 description 12
230000006870 function Effects 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 10
210000002257 embryonic structure Anatomy 0.000 description 10
230000001105 regulatory effect Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 9
210000002459 blastocyst Anatomy 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
239000013598 vector Substances 0.000 description 9
238000004458 analytical method Methods 0.000 description 8
210000004602 germ cell Anatomy 0.000 description 8
239000013615 primer Substances 0.000 description 8
239000000523 sample Substances 0.000 description 8
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 7
230000004913 activation Effects 0.000 description 7
238000001994 activation Methods 0.000 description 7
230000000903 blocking effect Effects 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
125000006239 protecting group Chemical group 0.000 description 7
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
102000004890 Interleukin-8 Human genes 0.000 description 6
108090001007 Interleukin-8 Proteins 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 6
239000002253 acid Substances 0.000 description 6
201000000028 adult respiratory distress syndrome Diseases 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000009849 deactivation Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
230000003834 intracellular effect Effects 0.000 description 6
210000001161 mammalian embryo Anatomy 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
238000010647 peptide synthesis reaction Methods 0.000 description 6
238000012216 screening Methods 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 5
102220585492 Short-chain dehydrogenase/reductase family 42E member 1_H5R_mutation Human genes 0.000 description 5
238000002105 Southern blotting Methods 0.000 description 5
239000000556 agonist Substances 0.000 description 5
230000004075 alteration Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
101150036876 cre gene Proteins 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000006801 homologous recombination Effects 0.000 description 5
238000002744 homologous recombination Methods 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
210000003101 oviduct Anatomy 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
241000699660 Mus musculus Species 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
239000004793 Polystyrene Substances 0.000 description 4
108091030071 RNAI Proteins 0.000 description 4
238000003556 assay Methods 0.000 description 4
229940049706 benzodiazepine Drugs 0.000 description 4
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
239000000969 carrier Substances 0.000 description 4
210000000038 chest Anatomy 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
235000013601 eggs Nutrition 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
230000009368 gene silencing by RNA Effects 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
208000027866 inflammatory disease Diseases 0.000 description 4
208000014674 injury Diseases 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
210000000287 oocyte Anatomy 0.000 description 4
229920002223 polystyrene Polymers 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
208000004852 Lung Injury Diseases 0.000 description 3
108010038807 Oligopeptides Proteins 0.000 description 3
102000015636 Oligopeptides Human genes 0.000 description 3
108090000284 Pepsin A Proteins 0.000 description 3
102000057297 Pepsin A Human genes 0.000 description 3
206010069363 Traumatic lung injury Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
210000003423 ankle Anatomy 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000010586 diagram Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000012173 estrus Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
238000003205 genotyping method Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000010354 integration Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
231100000515 lung injury Toxicity 0.000 description 3
238000000520 microinjection Methods 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
150000002894 organic compounds Chemical class 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000010410 reperfusion Effects 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
238000012552 review Methods 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101150009981 C5AR1 gene Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
108010047041 Complementarity Determining Regions Proteins 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108091006027 G proteins Proteins 0.000 description 2
102000030782 GTP binding Human genes 0.000 description 2
108091000058 GTP-Binding Proteins 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
238000010222 PCR analysis Methods 0.000 description 2
238000002944 PCR assay Methods 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000004365 Protease Substances 0.000 description 2
206010037423 Pulmonary oedema Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
210000000625 blastula Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000002975 chemoattractant Substances 0.000 description 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
230000029087 digestion Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
102000056190 human C5AR1 Human genes 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
229940125425 inverse agonist Drugs 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000013011 mating Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000030503 positive regulation of chemotaxis Effects 0.000 description 2
230000025726 positive regulation of exocytosis Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
208000005333 pulmonary edema Diseases 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
238000005316 response function Methods 0.000 description 2
208000013223 septicemia Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000007781 signaling event Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
229910052716 thallium Inorganic materials 0.000 description 2
230000008719 thickening Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
238000011282 treatment Methods 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 1
102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108010051219 Cre recombinase Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
208000003870 Drug Overdose Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
241000581650 Ivesia Species 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
108091027974 Mature messenger RNA Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033296 Overdoses Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108090001109 Thermolysin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010069351 acute lung injury Diseases 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004671 cell-free system Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229940126681 complement 5a receptor antagonist Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
231100000725 drug overdose Toxicity 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
150000001469 hydantoins Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
230000007574 infarction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004199 lung function Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000012900 molecular simulation Methods 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
210000000472 morula Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
239000012268 protein inhibitor Substances 0.000 description 1
229940121649 protein inhibitor Drugs 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
ISHLCKAQWKBMAU-UHFFFAOYSA-N tert-butyl n-diazocarbamate Chemical compound CC(C)(C)OC(=O)N=[N+]=[N-] ISHLCKAQWKBMAU-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
210000003014 totipotent stem cell Anatomy 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
150000003673 urethanes Chemical class 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
210000004340 zona pellucida Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Environmental Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Endocrinology (AREA)
Biodiversity & Conservation Biology (AREA)
Microbiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Rheumatology (AREA)
Public Health (AREA)
Pathology (AREA)
Plant Pathology (AREA)
Animal Husbandry (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES10196615.8T 2003-12-24 2004-12-24 Ratón transgénico que comprende un polinucleótido que codifica C5aR humano o humanizado Expired - Lifetime ES2587344T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AU2003907150		2003-12-24
AU2003907150A AU2003907150A0 (en)		2003-12-24	Transgenic mammals

Publications (1)

Publication Number	Publication Date
ES2587344T3 true ES2587344T3 (es)	2016-10-24

Family

ID=44122644

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES10196615.8T Expired - Lifetime ES2587344T3 (es)	2003-12-24	2004-12-24	Ratón transgénico que comprende un polinucleótido que codifica C5aR humano o humanizado
ES04802145T Expired - Lifetime ES2364335T3 (es)	2003-12-24	2004-12-24	Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES04802145T Expired - Lifetime ES2364335T3 (es)	2003-12-24	2004-12-24	Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado.

Country Status (3)

Country	Link
JP (2)	JP4936899B2 (de)
AT (1)	ATE510020T1 (de)
ES (2)	ES2587344T3 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR201901782T4 (tr)	2013-09-23	2019-03-21	Regeneron Pharma	İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
IL287519B2 (en)	2014-06-19	2024-01-01	Regeneron Pharma	Non-human animals having a humanized programmed cell death 1 gene
CN113412818B (zh) *	2014-12-09	2022-11-04	瑞泽恩制药公司	具有人源化分化簇274基因的非人动物
CN119120576A (zh) *	2024-11-12	2024-12-13	上海南方模式生物科技股份有限公司	一种c5ar1基因人源化动物模型的构建方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998033908A1 (en) *	1997-01-31	1998-08-06	Incyte Pharmaceuticals, Inc.	Human c5a-like receptor
EP1581648A2 (de) *	2002-09-09	2005-10-05	Nura, Inc.	G-protein-gekoppelte rezeptoren und deren verwendung
WO2004023973A2 (en) *	2002-09-12	2004-03-25	Incyte Corporation	Molecules for diagnostics and therapeutics
US20040253606A1 (en) *	2002-11-26	2004-12-16	Protein Design Labs, Inc.	Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20040157253A1 (en) *	2003-02-07	2004-08-12	Millennium Pharmaceuticals, Inc.	Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
DE10309729A1 (de) *	2003-02-26	2004-09-16	Hinzmann, Bernd, Dr.	Humane Nukleinsäuresequenzen aus Harnblasenkarzinomen
WO2004082568A2 (en) *	2003-03-17	2004-09-30	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)

2004
- 2004-12-24 ES ES10196615.8T patent/ES2587344T3/es not_active Expired - Lifetime
- 2004-12-24 JP JP2006545851A patent/JP4936899B2/ja not_active Expired - Fee Related
- 2004-12-24 ES ES04802145T patent/ES2364335T3/es not_active Expired - Lifetime
- 2004-12-24 AT AT04802145T patent/ATE510020T1/de not_active IP Right Cessation
2011
- 2011-10-06 JP JP2011221518A patent/JP5796240B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP4936899B2 (ja)	2012-05-23
JP2012050451A (ja)	2012-03-15
ES2364335T3 (es)	2011-08-31
JP2007520212A (ja)	2007-07-26
ATE510020T1 (de)	2011-06-15
JP5796240B2 (ja)	2015-10-21

Publication	Publication Date	Title
ES2284161T3 (es)	2007-11-01	Generacion de anticuerpos xenogenicos.
AU2009201840A1 (en)	2009-06-04	Transgenic Non-Human Mammal comprising a polynucleotide encoding human or humanized C5aR
US20110219465A1 (en)	2011-09-08	Suppression of B-Cell Apoptosis in Transgenic Animals Expressing Humanized Immunoglobulin
JPH06505870A (ja)	1994-07-07	形質転換された魚類の製造用の遺伝子構築体
KR20110020860A (ko)	2011-03-03	유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
CN107529739A (zh)	2018-01-02	表达人特定分子和人Fcγ受体家族的转基因非人动物
CA2562482A1 (en)	2005-12-01	Novel gene disruptions, compositions and methods relating thereto
ES2323158T3 (es)	2009-07-07	Alk-7 (quinasa analoga a la activina), un receptor de la serina treonina quinasa.
AU2005213965B2 (en)	2009-11-19	Gene disruptions, compositions and methods relating thereto
ES2809774T3 (es)	2021-03-05	Roedores con alelos mutantes de Acvr1 condicionales
JP5796240B2 (ja)	2015-10-21	ヒトまたはヒト化Ｃ５ａＲをコードするポリヌクレオチドを含むトランスジェニック非ヒト哺乳動物
JP7504030B2 (ja)	2024-06-21	進行性骨化性線維異形成症のげっ歯類モデル
Charreau et al.	1996	Analysis of human CD59 tissue expression directed by the CMV-IE-1 promoter in transgenic rats
US20100107265A1 (en)	2010-04-29	Double-muscling in mammals
Andrä et al.	2002	Generation and characterization of transgenic mice expressing cobra venom factor
CA2196190A1 (en)	1996-02-15	Ikaros transgenic cells and animals
US20100286051A1 (en)	2010-11-11	MEMORY AND LEARNING IMPAIRMENTS ASSOCIATED WITH DISRUPTION OF EPHRIN RECEPTOR A6 (EphA6) GENE
CN118956959A (zh)	2024-11-15	一种ifnar1和/或ifnar2基因修饰的非人动物
Economides	2002	The role of Hoxb13 in caudal axis patterning and prostate development
Zerucha	2001	Evolution of auto- and cross-regulatory elements of members of the distal-less-related family of homeobox-containing genes.
Perkins	1993	Further characterization of the murine embryonic lethal mutation, H beta 58, and its role in the visceral yolk sac
MXPA98004115A (en)	1999-06-01	Purification of more elevated order transcription compositions from transgenic animals no huma
JP2001048803A (ja)	2001-02-20	医薬